-transparent.png){kind=logo}
Ketotifen in a dose of 1 mg p.o. q 12 h was compared with placebo in a double-blind, twelve month parallel group trial in 17 randomly selected patients with bronchial asthma. Among 13 patients treated with ketotifen, nine have been classified as responders and four as non-responders. Responders were young and teenaged individuals, athletically oriented, with moderate asthma. It is our impression that ketotifen offers a new therapeutic dimension in the prophylaxis of bronchial asthma.
Related Publications
W K Podleski, and
T M Zelenak, and
J L Schmidt
January 1983,
Alergia,
W K Podleski, and
T M Zelenak, and
J L Schmidt
February 1980,
Schweizerische medizinische Wochenschrift,
W K Podleski, and
T M Zelenak, and
J L Schmidt
January 1980,
Respiration; international review of thoracic diseases,
W K Podleski, and
T M Zelenak, and
J L Schmidt
January 1989,
Sovetskaia meditsina,
W K Podleski, and
T M Zelenak, and
J L Schmidt
November 1996,
Indian pediatrics,
W K Podleski, and
T M Zelenak, and
J L Schmidt
January 1979,
Allergologia et immunopathologia,
W K Podleski, and
T M Zelenak, and
J L Schmidt
August 1990,
The Journal of allergy and clinical immunology,
W K Podleski, and
T M Zelenak, and
J L Schmidt
January 1982,
Clinical therapeutics,
W K Podleski, and
T M Zelenak, and
J L Schmidt
March 1987,
La Clinica terapeutica,
W K Podleski, and
T M Zelenak, and
J L Schmidt
November 1984,
La Clinica terapeutica,
